Document is current
Any future updates will be listed below
-
Authors
Eichenauer, Dennis A. https://orcid.org/0000-0002-1927-3514
Basaran, Aylin
Bühnen, Ina
Fuchs, Michael https://orcid.org/0000-0003-3289-3272
von Tresckow, Bastian https://orcid.org/0000-0003-1410-4487
Rosenwald, Andreas
Hansmann, Martin-Leo
Bernd, Heinz-Wolfram
Borchmann, Peter
Klapper, Wolfram https://orcid.org/0000-0001-7208-4117
Hartmann, Sylvia https://orcid.org/0000-0003-3424-1091
- License Information
-
More Information
Article History
Received: 24 February 2025
Revised: 23 April 2025
Accepted: 1 May 2025
First Online: 13 May 2025
Competing interests
: DAE received honoraria from Takeda; BvT is an advisor or consultant for Allogene, Amgen, BMS/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, Pentixapharm, Pfizer, Pierre Fabre, Qualworld, Regeneron, Roche, Sobi and Takeda; has received honoraria from AbbVie, AstraZeneca, BMS/Celgene, Gilead Kite, Incyte, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Roche and Takeda; reports research funding from Esteve (Inst), Merck Sharp & Dohme (Inst), Novartis (Inst), and Takeda (Inst); and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Pierre Fabre, Roche, Takeda, and Novartis; is member of steering committees for Regeneron and Takeda; the other authors report no potential competing interests
